Poorly differentiated endocrine carcinoma of the pancreas responded to gemcitabine: Case report

Nakazuru, Shoichi; Yoshio, Toshiyuki; Suemura, Shigeki; Itoh, Mari; Araki, Mikiya; Yoshioka, Chiaki; Ohta, Makiyo; Sueyoshi, Yuka; Ohta, Takashi; Hasegawa, Hiroko; Morita, Kiyozo; Toyama, Takashi; Kuzushita, Noriyoshi; Kodama, Yoshinori; Mano, Masayuki; Mita, Eiji

doi:10.3748/wjg.v16.i30.3853

Cited by 3 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All of the studies concurringly found Gemcitabine to be well tolerated, with a favorable side-effects profile [ 33 , 34 , 35 ]. Concerning pNEC in particular, data are currently lacking; however, several case-reports observed a response and satisfactory tolerability to treatment with Gemcitabine as a salvage therapy [ 36 ], third-line therapy [ 37 ] or in combination with S-1 [ 38 , 39 ].…”

Section: Discussionmentioning

confidence: 99%

New Therapy Options for Neuroendocrine Carcinoma of the Pancreas—The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo

Buchholz

Strotmann

Majchrzak-Stiller

et al. 2022

Cancers

View full text Add to dashboard Cite

Neuroendocrine carcinoma of the pancreas (pNEC) is an aggressive form of neuroendocrine tumor characterized by a rising incidence without an increase in survival rates. GP-2250 is an oxathiazinane derivate possessing antineoplastic effects, especially in combination with Gemcitabine on the pancreatic adenocarcinoma. The cytotoxic effects of the monotherapy of GP-2250 (GP-2250mono) and Gemcitabine (Gemmono), as well as the combination therapy of both, were studied in vitro using an MTT-assay on the QGP-1 and BON-1 cell lines, along with in vivo studies on a murine xenograft model of QGP-1 and a patient-derived xenograft model (PDX) of Bo99. In vitro, Gemmono and GP-2250mono showed a dose-dependent cytotoxicity. The combination of GP-2250 and Gemcitabine exhibited highly synergistic effects. In vivo, the combination therapy obtained a partial response in QGP-1, while GP-2250mono and Gemmono showed progressive disease or stable disease, respectively. In Bo99 PDX, the combination therapy led to a partial response, while the monotherapy resulted in progressive disease. No development of secondary resistances was observed, as opposed to monotherapy. This study was the first to evaluate the effects of the emerging substance GP-2250 on pNEC. The substance showed synergism in combination with Gemcitabine. The combination therapy proved to be effective in vitro and in vivo, without the development of secondary resistances.

show abstract

Section: Discussionmentioning

confidence: 99%

New Therapy Options for Neuroendocrine Carcinoma of the Pancreas—The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo

Buchholz

Strotmann

Majchrzak-Stiller

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Overexpression of MRTF-A and –B promoted pancreatic cancer growth in a nude mouse assay, and high expression of MRTFs in pancreatic cancer cell lines is associated with resistance to the chemotherapeutic agent gemcitabine [ 39 ]. Alteration towards a more stem cell-like phenotype and increased drug resistance is meaningful since less differentiated tumours tend to be more aggressive and typically respond poorly to traditional chemotherapeutics [ 40 ].…”

Section: Myocardin-related Transcription Factor (Mrtf) Familymentioning

confidence: 99%

Framework to function: mechanosensitive regulators of gene transcription

Finch-Edmondson

Sudol

2016

Cell Mol Biol Lett

View full text Add to dashboard Cite

Mechanobiology has shifted our understanding of fundamental cellular and physiological functions. Changes to the stiffness of the extracellular matrix, cell rigidity, or shape of the cell environment were considered in the past to be a consequence of aging or pathological processes. We now understand that these factors can actually be causative biological mediators of cell growth to control organ size. Mechanical cues are known to trigger a relatively fast translocation of specific transcriptional co-factors such as MRTFs, YAP and TAZ from the cytoplasm to the cell nucleus to initiate discrete transcriptional programs. The focus of this review is the molecular mechanisms by which biophysical stimuli that induce changes in cytoplasmic actin dynamics are communicated within cells to elicit gene-specific transcription via nuclear localisation or activation of specialized transcription factors, namely MRTFs and the Hippo pathway effectors YAP and TAZ. We propose here that MRTFs, YAP and TAZ closely collaborate as mechano-effectors.

show abstract

Gemcitabine as Salvage Treatment in Patients with Poorly Differentiated Pancreatic Neuroendocrine Tumors: A Case Series

Saif

Kaley

Rodrı́guez

et al. 2014

JOP. Journal of the Pancreas

View full text Add to dashboard Cite

Poorly differentiated endocrine carcinoma of the pancreas responded to gemcitabine: Case report

Cited by 3 publications

References 20 publications

New Therapy Options for Neuroendocrine Carcinoma of the Pancreas—The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo

New Therapy Options for Neuroendocrine Carcinoma of the Pancreas—The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo

Framework to function: mechanosensitive regulators of gene transcription

Gemcitabine as Salvage Treatment in Patients with Poorly Differentiated Pancreatic Neuroendocrine Tumors: A Case Series

Contact Info

Product

Resources

About